Currently, ICMR headquarters is conducting a multicentral trial in order to study the efficacy and safety of two tuberculosis (TB) vaccines, vpm1002 and Immuvac. This is conducted in 18 sites in India across six different states: Dr Suchit Kamble, Scientist, ICMR-NARI pic.twitter.com/ATdMLuylXc— ANI (@ANI) April 1, 2022
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


